TY  - GEN
AU  - Wykoff,Charles C
AU  - Brown,David M
AU  - Chen,Eric
AU  - Major,James C
AU  - Croft,Daniel E
AU  - Mariani,Angeline
AU  - Wong,Tien P
TI  - SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results
SN  - 2325-8179
PY  - 2013///0710
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Drug Resistance
KW  - Female
KW  - Fluorescein Angiography
KW  - History, 18th Century
KW  - Humans
KW  - Intravitreal Injections
KW  - Male
KW  - Prospective Studies
KW  - Ranibizumab
KW  - Refraction, Ocular
KW  - Tomography, Optical Coherence
KW  - Vascular Endothelial Growth Factor A
KW  - antagonists & inhibitors
KW  - Visual Acuity
KW  - physiology
KW  - Wet Macular Degeneration
KW  - diagnosis
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Historical Article; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3928/23258160-20130313-04
ER  -